Citations

Clear

382 citation(s) found for "Shapiro, R".

Quantitative T2 MRI Mapping and 12-Month Follow-up in a Randomized, Blinded, Placebo Controlled Trial of Bone Marrow Aspiration and Concentration for Osteoarthritis of the Knees
Arthurs, Jennifer R. , Kazmerchak, Shari E. , Diehl, Nancy N. , O’Connor, Mary I. , Bestic, Joseph M. , O'Connor, Mary I , Shapiro, Shane A. , Heckman, Michael G. , Zubair, Abba C.

Mayo Clinic

CARTILAGE | August 30, 2018 | Volume: 10 | Issue: 4 | Pages: 432-443

10.1177/1947603518796142 | PMID 30160168 Get It

Objective Bone marrow aspiration and concentration (BMAC) is becoming a more common regenerative therapy for musculoskeletal pathology. In our current pilot study, we studied patients with mild-to-moderate bilateral knee osteoarthritis, compared pain at 12-month follow-up between BMAC-injected and saline-injected knees, and examined cartilage appearance measured by magnetic resonance imaging (MRI) T2 quantitative mapping. Design Twenty-five patients with mild-to-moderate bilateral osteoarthritic knee pain were randomized to receive BMAC into one knee and saline placebo into the other. Bone marrow was aspirated from the iliac crests, concentrated in an automated centrifuge, combined with platelet-poor plasma for knee injection, and compared with saline injection into the contralateral knee. Primary outcome measures were T2 MRI cartilage mapping at 6-month and Visual Analog Scale and Osteoarthritis Research Society International Intermittent and Constant Osteoarthritis Pain scores and radiographs at 12-month follow-up. Results Constant, intermittent, and overall knee pain remained significantly decreased from baseline at 12-month follow-up (all P ⩽ 0.01), with no apparent difference between BMAC- and saline-treated knees (all P ⩾ 0.54). A similar significant increase from baseline to 12-month follow-up regarding quality of life was observed for both BMAC- and saline-treated knees (all P ⩽ 0.04). T2 quantitative MRI mapping showed no significant changes as a result of treatment. Conclusions BMAC is safe to perform and relieves pain from knee arthritis but showed no superiority to saline injection at 12-month follow-up. MRI cartilage sequences failed to show regenerative benefit with single BMAC injection. The mechanisms of action that led to pain relief remain unclear and warrant further studies.
Regenerative Medicine in the State of Florida: Letter Outlining the Florida Organization for Regenerative Medicine
Bu, Guojun , Centanni, John M., Davis, Mary Dabney , Hare, Joshua M. , Fields, Gregg , Jove, Richard, Kenyon, Norma S. , Khan, Aisha , March, Keith L. , Mahmood, Ayesha, Pepine, Carl J. , Zylberberg, Claudia, Zylberberg, Ezequiel, Bruce, Charles J. , Davis, Mary D, Zylberberg, Ezequiel , Bu, Guojun , Davis, Mary D., Dobson, Jon , Matosevic, Sandro , Ricordi, Camillo , Shapiro, Shane A.

Mayo Clinic

Stem Cells Translational Medicine | July 19, 2018 | Volume: 7 | Issue: 7 | Pages: 511-512

10.1002/sctm.18-0066 | PMID 30403444 Get It

Faculty Opinions recommendation of Identification of Cellular Sources of IL-2 Needed for Regulatory T Cell Development and Homeostasis.
Dash, Barsha, Shapiro, Virginia Smith

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | June 27, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.733181387.793547504 Get It

Micro-fragmented adipose tissue for treatment of knee osteoarthritis with Baker’s cyst: a case study
Arthurs, Jennifer R. , Desmond, Cheryl M, TerKonda, Sarvam P. , Desmond, Cheryl M., Shapiro, Shane A.

Mayo Clinic

BMJ Case Reports | June 4, 2018 | Volume: 2018 | Issue: No issue available | Pages: bcr-2018-224426

10.1136/bcr-2018-224426 | PMID 29866683 Get It

Adipose-derived therapies have increased in popularity for treatment of painful orthopaedic conditions, such as osteoarthritis. We report the passage of fat into a Baker’s cyst after injection of micro-fragmented adipose tissue in a patient with bilateral knee arthritis. Following fat grafting, the patient required drainage of fatty fluid from within the Baker’s cyst on multiple occasions. Approximately 3 months postprocedure, she began to notice an improvement in her knee pain with no further recurrence of pain or swelling from her Baker’s cyst.
Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health
Larkin, Lisa , Stuenkel, Cynthia A. , Bachmann, Gloria , Chism, Lisa Astalos, Kagan, Risa , Kaunitz, Andrew M., Krychman, Michael , Parish, Sharon J. , Pinkerton, JoAnn V. , Rowen, Tami S., Shapiro, Marla , Simon, James A. , Goldfarb, Shari, Kingsberg, Sheryl A. , Faubion, Stephanie S. , Partridge, Ann H.

Mayo Clinic

Menopause | May 15, 2018 | Volume: 25 | Issue: 6 | Pages: 596-608

10.1097/gme.0000000000001121 | PMID 29762200 Get It

Abstract The objective of The North American Menopause Society (NAMS) and The International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel was to create a point of care algorithm for treating genitourinary syndrome of menopause (GSM) in women with or at high risk for breast cancer. The consensus recommendations will assist healthcare providers in managing GSM with a goal of improving the care and quality of life for these women. The Expert Consensus Panel is comprised of a diverse group of 16 multidisciplinary experts well respected in their fields. The panelists individually conducted an evidence-based review of the literature in their respective areas of expertise. They then met to discuss the latest treatment options for genitourinary syndrome of menopause (GSM) in survivors of breast cancer and review management strategies for GSM in women with or at high risk for breast cancer, using a modified Delphi method. This iterative process involved presentations summarizing the current literature, debate, and discussion of divergent opinions concerning GSM assessment and management, leading to the development of consensus recommendations for the clinician. Genitourinary syndrome of menopause is more prevalent in survivors of breast cancer, is commonly undiagnosed and untreated, and may have early onset because of cancer treatments or risk-reducing strategies. The paucity of evidence regarding the safety of vaginal hormone therapies in women with or at high risk for breast cancer has resulted in avoidance of treatment, potentially adversely affecting quality of life and intimate relationships. Factors influencing decision-making regarding treatment for GSM include breast cancer recurrence risk, severity of symptoms, response to prior therapies, and personal preference. We review current evidence for various pharmacologic and nonpharmacologic therapeutic modalities in women with a history of or at high risk for breast cancer and highlight the substantial gaps in the evidence for safe and effective therapies and the need for future research. Treatment of GSM is individualized, with nonhormone treatments generally being first line in this population. The use of local hormone therapies may be an option for some women who fail nonpharmacologic and nonhormone treatments after a discussion of risks and benefits and review with a woman's oncologist. We provide consensus recommendations for an approach to the management of GSM in specific patient populations, including women at high risk for breast cancer, women with estrogen-receptor positive breast cancers, women with triple-negative breast cancers, and women with metastatic disease.
Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial)
Shapiro, Brian P. , Ambrosius, Walter T. , Blackshear, Joseph L., Whelton, Paul K. , Oparil, Suzanne , Dwyer, Jamie P. , Kostis, William J. , Lioudis, Michael , Pisoni, Roberto, Rosendorff, Clive , Haley, William E. , Dwyer, Jamie P , Cushman, William C. , Beddhu, Srinivasan , Gren, Lisa H.

Mayo Clinic

Hypertension | April 30, 2018 | Volume: 71 | Issue: 6 | Pages: 1064-1074

10.1161/hypertensionaha.117.10646 | PMID 29712745 Get It

Intensive systolic blood pressure (SBP) control improved outcomes in SPRINT (Systolic Blood Pressure Intervention Trial). Our objective was to expand on reported findings by analysis of baseline characteristics, primary outcomes, adverse events, follow-up blood pressure, and medication use differences by baseline SBP (tertile 1 [T1], <132; tertile 2 [T2], 132–145; and tertile 3 [T3], >145 mm Hg). Participants with higher baseline SBP tertile were more often women and older, had higher cardiovascular risk, and lower utilization of antihypertensive medications, statins, and aspirin. Achieved SBP in both treatment arms was slightly higher in T2 and T3 compared with T1 and fewer in the T3 groups achieved SBP targets compared with T1 and T2 groups. The primary composite outcome with intensive versus standard SBP treatment was reduced by 30% in T1, 23% in T2, and 17% in T3 with no evidence of an interaction ( P =0.77). Event rates were lower in the intensive arm, and there was no evidence that this benefit differed by SBP tertile. There was no difference in the hazard for serious adverse events in any of the 3 tertiles. Medication utilization differed across the SBP tertiles at baseline with a lesser percentage of diuretics and angiotensin-converting enzyme inhibitors/angiotensin receptor blocker drugs in the higher tertiles—a finding that reversed during the trial. The beneficial effects of intensive SBP lowering were not modified by the level of baseline SBP. Within the parameters of this population, these findings add support for clinicians to treat blood pressure to goal irrespective of baseline SBP.
A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
Shapiro, Geoffrey I. , Bullock, Andrea J. , Rock, Edwin P. , Elekes, Agnes, Lin, Chester, Kostic, Dušan , Ohi, Naoto, Rasco, Drew , Papadopoulos, Kyriakos P. , Patnaik, Amita , Smith, Lon, Tolcher, Anthony W. , Flaherty, Keith T. , Berlin, Jordan D. , Witzig, Thomas E. , Habermann, Thomas M. , Ohi, Naoto, Coté, Gregory M. , Shapiro, Geoffrey I

Mayo Clinic

The Oncologist | March 6, 2018 | Volume: 23 | Issue: 6 | Pages: 658-e72

10.1634/theoncologist.2017-0325 | PMID 29511132 Get It

Abstract Lessons Learned OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation that exhibited promising anticancer activity in preclinical models. In this first-in-human phase I study of OPB-111077 in unselected advanced cancers, treatment-emergent adverse events, most frequently nausea, fatigue, and vomiting, were generally mild to moderate in intensity and could be medically managed. Overall, only modest clinical activity was observed after OPB-111077 given as monotherapy. Notable antitumor activity was seen in a subject with diffuse large B-cell lymphoma. Background OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation with promising anticancer activity in preclinical models. Methods Open-label, phase I trial of OPB-111077 in advanced cancers with no available therapy of documented benefit. Initial dose escalation in unselected subjects was followed by dose expansion. Patients received oral OPB-111077 daily in 28-day cycles until loss of clinical benefit. Results Eighteen subjects enrolled in dose escalation, and 127 in dose expansion. Dose-limiting toxicities were observed at 300 mg and 400 mg QD; maximum tolerated dose was defined as 250 mg QD. Frequently reported treatment-emergent adverse events (TEAEs) included nausea, fatigue, and vomiting. TEAEs were generally mild to moderate and could be medically managed. OPB-111077 reached micromolar drug concentrations, had an elimination half-life of approximately 1 day, and reached steady-state by day 8. A durable partial response was observed in one subject with diffuse large B-cell lymphoma. Seven subjects with diverse tumor types had stable disease or minor responses for at least eight treatment cycles (224 days). Conclusion OPB-111077 is generally well tolerated, and its pharmacokinetic profile is sufficient for further clinical development. Notable clinical activity was observed in a subject with diffuse large B-cell lymphoma. Overall, modest efficacy was observed against unselected tumors.
Reply to L. Kennedy et al
Moriarty, James P. , Shapiro, Charles L. , Borah, Bijan J.

Mayo Clinic

Journal of Clinical Oncology | February 1, 2018 | Volume: 36 | Issue: 10 | Pages: 1052-1053

10.1200/jco.2017.77.2749 | PMID 29389230 Get It

Spinal artery aneurysms: clinical presentation, radiological findings and outcome
Renieri, Leonardo , Raz, Eytan , Shapiro, Maksim , Shirani, Peyman, Brinjikji, Waleed , Renieri, Leonardo , Lanzino, Giuseppe , Krings, Timo

Mayo Clinic

Journal of NeuroInterventional Surgery | January 30, 2018 | Volume: 10 | Issue: 7 | Pages: 646-650

10.1136/neurintsurg-2017-013687 | PMID 29382773 Get It

Background and purpose Spinal arterial aneurysms are a rare cause of spinal subarachnoid hemorrhage (SAH). We performed a retrospective review of spinal arterial aneurysms not associated with spinal arteriovenus shunts from three institutions in order to better understand the clinical and imaging characteristics of these lesions. Materials and methods We performed a retrospective review of spinal arterial aneurysms managed at three North American institutions. For each patient, the following information was collected: demographic data, clinical presentation, comorbidities, imaging findings, and neurological status at the last follow-up. Treatment strategies and outcomes were reported. Results 11 patients were included; 7 were women and median age was 60 years. The most common presentation was sudden back pain (81.8%). We found 3 aneurysms on the radiculomedullary artery and 8 along the radiculopial arteries. Of the 3 aneurysms on the radiculomedullary artery, 1 was treated conservatively, 1 was treated with coiling of the aneurysm and sacrifice of the radiculomedullary artery, and 1 was treated with surgical trapping. The 8 aneurysms on the radiculopial artery were treated endovascularly in 4 cases, surgically in 1 case, and conservatively in 3 cases. One surgically treated patient had a spinal subdural hematoma. There were no other complications. Mean clinical follow-up time was 20 months, and 87.5% of patients were functionally independent. Conclusions Spinal arterial aneurysms are lesions which commonly present with sudden back pain and spinal SAH. Conservative, surgical, and endovascular treatment options are safe and effective. Long term outcomes in these patients are generally good.